Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b clinical study for REVTx-100 for the prevention of surgical site infection in colorectal surgery

Next Previous
X
Search
Trial Profile

Phase 1b clinical study for REVTx-100 for the prevention of surgical site infection in colorectal surgery

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glycopyranosyl lipid adjuvant (Primary)
  • Indications Postoperative infections
  • Focus Adverse reactions
  • Acronyms GEMINI-PSI program

    • Most Recent Events

    • 01 Feb 2024 According to a Revelation Biosciences media release, gross proceeds to the Company from the offering are approximately $6.2 million, intends to use the net proceeds to further the development of this phase1a combination study.
    • 22 May 2023 According to a Revelation Biosciences media release, the company expect to initiate this study in Q4 of this year.
    • 30 Mar 2023 According to a Revelation Biosciences media release, the company expects to file an IND by the end of 2023 to support this study,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top